Skip to main content
Fig. 1 | Advances in Rheumatology

Fig. 1

From: Efficacy and safety of different Janus kinase inhibitors combined with methotrexate for the treatment of rheumatoid arthritis: a single-center randomized trial

Fig. 1

Percentages of the rheumatoid arthritis patients in the baricitinib (a) and tofacitinib (b) groups with the disease activity score in 28 joints, C-reactive protein (DAS28-CRP) score ≤ 2.6, > 2.6–3.2, > 3.2–5.1, and > 5.1 at baseline and after 3 and 6 months of treatment

Back to article page

Advances in Rheumatology

ISSN: 2523-3106